Transcranial Magnetic Stimulation for Major Depressive Disorder: A Pragmatic Approach to Implementing TMS in a Clinical Practice. Ann Clin Psychiatry. 2010 Nov;22(4 Suppl):S4-11.

Another option for managing major depressive disorder (MDD) became available in October 2008 with the Food and Drug Administration’s (FDA) market clearance of NeuroStar TMS (transcranial magnetic stimulation) Therapy System. A panel of psychiatrists who have been treating patients with NeuroStar TMS Therapy in their clinics assembled for a virtual roundtable discussion regarding their experiences. In this supplement, the panel addresses the following issues: the FDA-cleared indication for use of NeuroStar TMS Therapy; logistic and staffing considerations in the outpatient setting; selecting the right patient for TMS Therapy; talking with patients and family about TMS Therapy. To give the overview a meaningful context, each panelist shares a personal account of a patient case, describing the treatment course and outcomes achieved with TMS Therapy.

Accelerated Repetitive Transcranial Magnetic Stimulation for Treatment Resistant Depression. Depression and Anxiety 27:960-963

Repetitive transcranial magnetic stimulation (rTMS) has shown safety and efficacy for treatment-resistant depression, but requires daily treatment for 4-6 weeks. Accelerated TMS, with all treatments delivered over a few days, would have significant advantages in terms of access and patient acceptance.

Demitrack, M.A. (2010) Transcranial Magnetic Stimulation for the Treatment of Major Depression clinical. Economic, and Practical Issues: Part II Psychopharm Review, Vol. 45, No. 8 August 2010

Part I of this two-part series (vol. 45, no. 4) discussed the clinical and economic burder of major depression; the compounding issue of treatment resistance; and cost analyses comparing transcranial magnetic stimulation (TMS) with standard clinical care (e.g., complex pharmacotherapy, electrconvulsive therapy [ECT]) for treatment resistance depression (TRD). Part II reviews practical issues in the clinical use of TMS, which have merged since its approval by the FDA for this indication.

Demitrack, M.A. (2010) Transcranial Magnetic Stimulation for the Treatment of Major Depression clinical. Economic, and Practical Issues: Part I Psychopharm Review, Vol. 45, No. 4 April 2010

This article is the first of two parts. Part I describes pervasive problems of major depression, the issue of treatment resistance and its economic impact. The article is intended to enable the reader to evaluate the epidemiology, functional health consequences, and economic burder of major depression, especially in its treatment-resistant form.